Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Mikus

Showing results (191-200 of 194) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 194 results.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2016
Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO)Thomas Schmitt, Regine Mayer-Steinacker, Frank Mayer, et al.
Oncoimmunology|April 11, 2018
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancerFriedrich H Schmitz-Winnenthal, Nicolas Hohmann, Thomas Schmidt, et al.
Clinical Pharmacology and Therapeutics|March 18, 2024
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM CohortAnna M Mc Laughlin, Thomas Helland, Fenja Klima, et al.
Oncoimmunology|July 3, 2015
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trialFriedrich H Schmitz-Winnenthal, Nicolas Hohmann, Andreas G Niethammer, et al.
Pageof 20

Showing results (191-200 of 194) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 194 results.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2016
Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO)Thomas Schmitt, Regine Mayer-Steinacker, Frank Mayer, et al.
Oncoimmunology|April 11, 2018
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancerFriedrich H Schmitz-Winnenthal, Nicolas Hohmann, Thomas Schmidt, et al.
Clinical Pharmacology and Therapeutics|March 18, 2024
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM CohortAnna M Mc Laughlin, Thomas Helland, Fenja Klima, et al.
Oncoimmunology|July 3, 2015
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trialFriedrich H Schmitz-Winnenthal, Nicolas Hohmann, Andreas G Niethammer, et al.
Pageof 20